| abstract |
The present invention relates to a method for determining a gene expression signature for diagnosing a patient with prostate cancer, e.g. to establish a prognosis for such a patient, for determining that the patient develops aggressive or indolent disease, e.g. after primary treatment and/or used to identify and rank patients for available therapies. The invention also relates to articles of manufacture, such as kits, software, etc., for use in such methods. The present invention also relates to treatments for treating patients who have been diagnosed, identified or graded in any of the methods disclosed herein. |